Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Free Report) has earned an average rating of “Buy” from the seven ratings firms that are covering the stock, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the […]